Wang Wei, Mo Wanying, Xiao Xue, Cai Manying, Feng Songfu, Wang Yupeng, Zhou Dongfang
NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Department of Ophthalmology & Department of Ultrasonic Diagnosis, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China.
Asian J Pharm Sci. 2024 Aug;19(4):100926. doi: 10.1016/j.ajps.2024.100926. Epub 2024 May 6.
Intracellular bacteria can multiply inside host cells and manipulate their biology, and the efficacy of traditional antibiotic drug therapy for intracellular bacteria is limited by inadequate drug accumulation. Fighting against these stealthy bacteria has been a long-standing challenge. Here, a system of stimuli-responsive lactoferrin (Lf) nanoparticles is prepared using protein self-assembly technology to deliver broad-spectrum antibiotic rifampicin (Rif) (Rif@Lf NPs) for enhanced infection therapy through targeted elimination of intracellular bacteria. Compared to Rif@BSA NPs, the Rif@Lf NPs can specifically target macrophages infected by bacteria, thus increasing the accumulation of Rif within macrophages. Subsequently, Rif@Lf NPs with positive surface charge further displayed targeted adherence to the bacteria within macrophages and released Rif rapidly in a redox-responsive manner. Combined with the antibacterial activities of Lf and Rif, the Rif@Lf NPs showed broad-spectrum antibiotic abilities to intracellular bacteria and biofilms. As a result, the Rif@Lf NPs with high safety exhibited excellent therapeutic efficacy in the disease models of subcutaneous infection, sepsis, and bacterial keratitis. Taken together, the antibiotic-loaded Lf nanoparticles present a promising platform to combat pathogen infections through targeted elimination of intracellular bacteria.
胞内细菌可在宿主细胞内繁殖并操控其生物学特性,而传统抗生素药物疗法对胞内细菌的疗效因药物蓄积不足而受限。对抗这些隐匿性细菌一直是一项长期挑战。在此,利用蛋白质自组装技术制备了一种刺激响应性乳铁蛋白(Lf)纳米颗粒系统,用于递送广谱抗生素利福平(Rif)(Rif@Lf NPs),以通过靶向清除胞内细菌增强感染治疗效果。与Rif@BSA NPs相比,Rif@Lf NPs可特异性靶向被细菌感染的巨噬细胞,从而增加Rif在巨噬细胞内的蓄积。随后,表面带正电荷的Rif@Lf NPs进一步表现出对巨噬细胞内细菌的靶向黏附,并以氧化还原响应方式快速释放Rif。结合Lf和Rif的抗菌活性,Rif@Lf NPs对胞内细菌和生物膜表现出广谱抗菌能力。因此,具有高安全性的Rif@Lf NPs在皮下感染、败血症和细菌性角膜炎疾病模型中表现出优异的治疗效果。综上所述,负载抗生素的Lf纳米颗粒为通过靶向清除胞内细菌对抗病原体感染提供了一个有前景的平台。
ACS Infect Dis. 2024-5-10
ACS Appl Mater Interfaces. 2023-8-30
Drug Deliv Transl Res. 2020-10
Invest Ophthalmol Vis Sci. 2021-11-1
Nanomaterials (Basel). 2024-12-16
J Funct Biomater. 2024-9-20
ACS Appl Mater Interfaces. 2023-2-15
Asian J Pharm Sci. 2022-11
J Control Release. 2022-11